LSD1 Antibody (A-2): sc-398794
- LSD1 Antibody (A-2) is a mouse monoclonal IgG2b κ, cited in 1 publications, provided at 200 µg/ml
- specific for an epitope mapping between amino acids 183-223 near the N-terminus of LSD1 of human origin
- recommended for detection of LSD1 of mouse, rat and human origin by WB, IP, IF and ELISA
- TransCruz reagent for ChIP application (sc-398794 X, 200 µg/0.1 ml)
- m-IgG2b BP-HRP is the preferred secondary detection reagent for LSD1 Antibody (A-2) for WB applications. This reagent is now offered in a bundle with LSD1 Antibody (A-2) (see ordering information below).
QUICK LINKS
SEE ALSO...
LSD1 Antibody (A-2) is a mouse monoclonal IgG2b light chain antibody that detects lysine-specific histone demethylase 1 (LSD1) in mouse, rat, and human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). LSD1 plays a crucial role in the regulation of chromatin structure and transcription by dynamically removing methyl groups from histone H3, thereby influencing gene expression and maintaining the epigenetic state of cells. LSD1′s unique structure includes a SWIRM domain, a flavin adenine dinucleotide (FAD)-binding motif, and an amine oxidase domain, which are essential for enzymatic activity and interaction with various regulatory proteins. Notably, LSD1 associates with CoREST, a corepressor that enhances demethylation activity and protects against degradation, highlighting the importance of protein-protein interactions in modulating LSD1′s function. Additionally, LSD1′s co-localization with androgen receptor in prostate cells underscores significance in androgen-receptor-dependent transcription, making LSD1 a vital player in both normal cellular processes and cancer biology. anti-LSD1 antibody (A-2) provides valuable insights into epigenetic regulation and transcriptional control, serving as an essential tool for researchers studying these complex biological mechanisms.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
LSD1 Antibody (A-2) References:
- Targeting oral cancer epigenome via LSD1. | Bais, MV. 2017. Aging (Albany NY). 9: 2455-2456. PMID: 29232656
- Pharmacological Inhibition of LSD1 for Cancer Treatment. | Yang, GJ., et al. 2018. Molecules. 23: PMID: 30518104
- Natural products as LSD1 inhibitors for cancer therapy. | Fang, Y., et al. 2020. Acta Pharm Sin B. 11: 621-31. PMID: 32837872
- Therapeutic potential of targeting LSD1/ KDM1A in cancers. | Zhang, X., et al. 2022. Pharmacol Res. 175: 105958. PMID: 34718134
- LSD1: Expanding Functions in Stem Cells and Differentiation. | Martinez-Gamero, C., et al. 2021. Cells. 10: PMID: 34831474
- Systemic LSD1 Inhibition Prevents Aberrant Remodeling of Metabolism in Obesity. | Ramms, B., et al. 2022. Diabetes. 71: 2513-2529. PMID: 36162056
- LSD1 defines the fiber type-selective responsiveness to environmental stress in skeletal muscle. | Araki, H., et al. 2023. Elife. 12: PMID: 36695573
- Lsd1 safeguards T-cell development via suppressing endogenous retroelements and interferon responses. | Xia, M., et al. 2023. Life Sci Alliance. 6: PMID: 37429639
- LSD1: an emerging face in altering the tumor microenvironment and enhancing immune checkpoint therapy. | Mamun, MAA., et al. 2023. J Biomed Sci. 30: 60. PMID: 37525190
- Neddylation-dependent LSD1 destabilization inhibits the stemness and chemoresistance of gastric cancer. | Guo, YJ., et al. 2024. Int J Biol Macromol. 254: 126801. PMID: 37689288
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
LSD1 Antibody (A-2) | sc-398794 | 200 µg/ml | $322.00 | |||
LSD1 Antibody (A-2): m-IgG2b BP-HRP Bundle | sc-548627 | 200 µg Ab; 10 µg BP | $361.00 | |||
LSD1 (A-2) Neutralizing Peptide | sc-398794 P | 100 µg/0.5 ml | $69.00 | |||
LSD1 Antibody (A-2) X | sc-398794 X | 200 µg/0.1 ml | $322.00 |